Stay updated with breaking news from Zymeworks Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In this article, we will take a detailed look at the 18 High Growth Low PE Stocks. For a quick overview of such stocks, read our article 5 High Growth Low PE Stocks. When value stocks came back with a vengeance in 2022, value investors cheered what they thought was the beginning of a long bull run of value […]
When value stocks came back with a vengeance in 2022, value investors cheered what they thought was the beginning of a long bull run of value stocks.
Dublin, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The
Durvalumab plus neoadjuvant FLOT improved pCR vs chemotherapy alone in patients with resectable gastric and GEJ cancers, irrespective of region.
Zymeworks Inc (NASDAQ:ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, recently witnessed a significant insider sell.